[PRC HOME]
 
University at Buffalo, the State University of New York School of Pharmacy and Pharmaceutical Sciences
 
Answers.com

 
  LCMSMS
Buprenorphine and Norbuprenorphine
Protease Inhibitor
Cortisol, Corticosteriods, Mycophenolic Acid and Mycophenolic Acid Glucuronide
Midazolam, Omeprazole and their Hydroxy Metabolites
Doxorubicin, Doxorubicinol, and Cyclophosphamide
Naltrexone and Naltrexol
Tenofovir

 

Doxorubicin, Doxorubicinol, and Cyclophosphamide

Simultaneous LCMSMS Method for Doxorubicin, Doxorubicinol, and Cyclophosphamide

Analyte

Lower Limit of Quantitation

(mg/L)

Acceptable Anticoagulants

Required PlasmaVolume

CV% low QC

Doxorubicin

0.00304

Heparinized Plasma (Na)

Minimal 1 mL*

5

Doxorubicinol

0.0072

5

Cyclophosphamide

0.44

10

Samples are prepared by solid phase extraction prior to chromatography. Internal standards are added to 0.4 mL of sample mixed with HCL solution prior to application onto a preconditioned Waters Oasis� HLB cartridge. The cartridge is rinsed with 5% methanol in HPLC grade water. The samples are then eluted with methanol and evaporated to dryness. The samples are reconstituted with a 75:25 mix of mobile phase A and acetonitrile, respectively. Twenty percent of the reconstituted samples are injected in the LCMSMS system.

Samples are analyzed on a Agilent HPLC system coupled to a Sciex API3000 triple quadupole mass analyzer used in the positive MRM mode. A gradient chromatography method separates the compounds from other components on a Waters Symmetry� C18 column. Each sample analysis requires 11 minutes.

 

 


© 2005 ePharmacotherapy Networks. All rights reserved.
371 Cooke Hall - Buffalo, NY 14260-1200
Last Modified: Monday, 09-Jul-2007 17:06:44 EDT
Usage Statistics